According to Biggar, Sanofi has suffered through a period in which two of its best selling drugs, Lantus (diabetes) and Plavix (prevention of blood clots) have seen their patents expire. The company also had to deal with legal issues, including a court ruling in which its cholesterol-lowering therapy Praluent infringed on patents held by rival pharmaceutical firm Amgen, Inc. (NASDAQ: AMGN).
Amgen 'Largely Moved Past' Prior Headwinds
Biggar now believes Amgen has "largely moved past" these events and investors can look forward to the company benefiting from the strong demand for its multiple sclerosis drugs and management's cost-cutting initiatives.
Biggar added that Amgen also boasts a strong pipeline of new drugs, including Toujeo, which is a next-generation insulin product. Other notable therapies in the pipeline include dipilumab for atopic dermatitis and other inflammatory conditions.
Valuation Is Attractive
Biggar further noted that Sanofi's stock is trading at 15.4x his 2017 earnings per ADS forecast which is short of the average multiple of 16.2x for S&P 500 Pharma companies. The analyst believes the stock shouldn't trade at a discount to the group average, rather it should trade at a slight premium given the company's positioning for growth.
Sanofi also pays investors a sustainable dividend which has been raised over the past 23 years and currently yields around 3.5 percent.
Argus Initiates Bioverativ With Hold
Here Are The 4 Commercial Launches In 2017 That Earned Tesaro A Buy Rating At Argus
Latest Ratings for SNY
|Apr 2017||Argus||Initiates Coverage On||Buy|
|Sep 2016||PiperJaffray||Initiates Coverage on||Neutral|
View More Analyst Ratings for SNY
View the Latest Analyst Ratings
See more from Benzinga
- 7-Eleven's .3 Billion Expansion In The U.S.
- Twitter Hopes To Grow In Emerging Markets With A 'Lite' Option
- BlackRock's Fink: Robots Will Supplement Humans In Stock Picking
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.